201 related articles for article (PubMed ID: 12375161)
1. Quinonic derivatives active against Toxoplasma gondii.
Sarciron ME; Nebois P; Pautet F; Pétavy AF; Fillion H; Walchshofer N
Parasitol Res; 2002 Nov; 88(11):969-71. PubMed ID: 12375161
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations.
Ling Y; Sahota G; Odeh S; Chan JM; Araujo FG; Moreno SN; Oldfield E
J Med Chem; 2005 May; 48(9):3130-40. PubMed ID: 15857119
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and in vitro activities of ferrocenic aminohydroxynaphthoquinones against Toxoplasma gondii and Plasmodium falciparum.
Baramee A; Coppin A; Mortuaire M; Pelinski L; Tomavo S; Brocard J
Bioorg Med Chem; 2006 Mar; 14(5):1294-302. PubMed ID: 16242338
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of 4-acyl-2-thiazolylhydrazone derivatives for anti-Toxoplasma efficacy in vitro.
Chimenti F; Bizzarri B; Bolasco A; Secci D; Chimenti P; Carradori S; Granese A; Rivanera D; Frishberg N; Bordón C; Jones-Brando L
J Med Chem; 2009 Aug; 52(15):4574-7. PubMed ID: 19618935
[TBL] [Abstract][Full Text] [Related]
5. Quinonic derivatives active against a virulent strain of Toxoplasma gondii. Synthesis of 2-methylfuro[2,3-g]- and [3,2-g]isoquinolinetriones.
Nebois P; Sarciron ME; Bibal B; Bouammali B; Cherkaoui O; Pautet F; Pétavy AF; Walchshofer N; Fillion H
Bioorg Med Chem Lett; 2000 May; 10(9):871-3. PubMed ID: 10853649
[TBL] [Abstract][Full Text] [Related]
6. In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
Meneceur P; Bouldouyre MA; Aubert D; Villena I; Menotti J; Sauvage V; Garin JF; Derouin F
Antimicrob Agents Chemother; 2008 Apr; 52(4):1269-77. PubMed ID: 18212105
[TBL] [Abstract][Full Text] [Related]
7. Toxoplasma gondii: the effect of fluconazole combined with sulfadiazine and pyrimethamine against acute toxoplasmosis in murine model.
Martins-Duarte ÉS; de Souza W; Vommaro RC
Exp Parasitol; 2013 Mar; 133(3):294-9. PubMed ID: 23270807
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Toxoplasma gondii by indirubin and tryptanthrin analogs.
Krivogorsky B; Grundt P; Yolken R; Jones-Brando L
Antimicrob Agents Chemother; 2008 Dec; 52(12):4466-9. PubMed ID: 18824607
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of thiosemicarbazone and 4-thiazolidinone derivatives and their in vitro anti-Toxoplasma gondii activity.
Tenório RP; Carvalho CS; Pessanha CS; de Lima JG; de Faria AR; Alves AJ; de Melo EJ; Góes AJ
Bioorg Med Chem Lett; 2005 May; 15(10):2575-8. PubMed ID: 15863319
[TBL] [Abstract][Full Text] [Related]
10. Original quinazoline derivatives displaying antiplasmodial properties.
Kabri Y; Azas N; Dumètre A; Hutter S; Laget M; Verhaeghe P; Gellis A; Vanelle P
Eur J Med Chem; 2010 Feb; 45(2):616-22. PubMed ID: 19926173
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of N-phenyl-1,10-phenanthroline-2-amines against tachyzoites and bradyzoites of Toxoplasma gondii.
Martins-Duarte ES; Portes JA; da Silva RB; Pires HS; Garden SJ; de Souza W
Bioorg Med Chem; 2021 Nov; 50():116467. PubMed ID: 34666274
[TBL] [Abstract][Full Text] [Related]
12. Induction of sulfadiazine resistance in vitro in Toxoplasma gondii.
Doliwa C; Escotte-Binet S; Aubert D; Velard F; Schmid A; Geers R; Villena I
Exp Parasitol; 2013 Feb; 133(2):131-6. PubMed ID: 23206954
[TBL] [Abstract][Full Text] [Related]
13. Molecular search of new active drugs against Toxoplasma gondii.
Gozalbes R; Gálvez J; García-Domenech R; Derouin F
SAR QSAR Environ Res; 1999; 10(1):47-60. PubMed ID: 10408126
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii.
Romand S; Pudney M; Derouin F
Antimicrob Agents Chemother; 1993 Nov; 37(11):2371-8. PubMed ID: 8285620
[TBL] [Abstract][Full Text] [Related]
15. 4-Arylthiosemicarbazide derivatives as a new class of tyrosinase inhibitors and anti-
Bekier A; Węglińska L; Paneth A; Paneth P; Dzitko K
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1145-1164. PubMed ID: 34074198
[TBL] [Abstract][Full Text] [Related]
16. Antiproliferative activities of two novel quinuclidine inhibitors against Toxoplasma gondii tachyzoites in vitro.
Martins-Duarte ES; Urbina JA; de Souza W; Vommaro RC
J Antimicrob Chemother; 2006 Jul; 58(1):59-65. PubMed ID: 16702175
[TBL] [Abstract][Full Text] [Related]
17. Development of an in vitro system to study the developmental stages of Toxoplasma gondii using a genetically modified strain expressing markers for tachyzoites and bradyzoites.
Portes JA; De Souza W
Parasitol Res; 2019 Dec; 118(12):3479-3489. PubMed ID: 31728720
[TBL] [Abstract][Full Text] [Related]
18. Thiolactomycin analogues as potential anti-Toxoplasma gondii agents.
Martins-Duarte ES; Jones SM; Gilbert IH; Atella GC; de Souza W; Vommaro RC
Parasitol Int; 2009 Dec; 58(4):411-5. PubMed ID: 19698800
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological characterization of thiazolidin-4-one derivatives as promising inhibitors of Toxoplasma gondii.
D'Ascenzio M; Bizzarri B; De Monte C; Carradori S; Bolasco A; Secci D; Rivanera D; Faulhaber N; Bordón C; Jones-Brando L
Eur J Med Chem; 2014 Oct; 86():17-30. PubMed ID: 25140751
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of anti-Toxoplasma gondii activity of a novel scaffold of thiazolidinone derivatives.
Carradori S; Secci D; Bizzarri B; Chimenti P; De Monte C; Guglielmi P; Campestre C; Rivanera D; Bordón C; Jones-Brando L
J Enzyme Inhib Med Chem; 2017 Dec; 32(1):746-758. PubMed ID: 28537532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
